Origin Therapeutics Holdings Inc. ORIG, a psychedelics industry-focused investment issuer, announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the FDA for its first Investigational New Drug (IND) application for a Phase 2a psilocybin therapy clinical study for anorexia nervosa.
Several companies are currently in clinical trial stages seeking a treatment for this deadly disorder that affects more women than men and for which there is no approved therapeutic regimen.
Origin Therapeutics CEO Alexander Somjen said is committed to safety, efficacy, and clinical expertise as the company seeks to become a global leader in the psychedelic treatment of eating disorders. He called the FDA approval “a major hurdle” in the development -and potential commercialization- on the path toward a new treatment for this condition.
Xpira's team includes industry professionals in North America and the Netherlands experienced in eating disorders, drug development, intellectual property, registration, product commercialization and specialty pharma.
Photo courtesy of Geralt on Pixabay.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!